Effect of Everolimus plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours - Analysis From RADIANT-2

Ítems similars

• EVEROLIMUS PLUS OCTREOTIDE LAR IN PATIENTS WITH LUNG CARCINOIDS
  per: Granberg, D, et al.
  Publicat: (2014)
• Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
  per: Fazio, N, et al.
  Publicat: (2013)
• The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
  per: Kaltsas, G, et al.
  Publicat: (2001)
• A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
  per: Turner, H, et al.
  Publicat: (1999)
• Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
  per: Chan, H, et al.
  Publicat: (2010)